Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study

Matthew Wilson, MD BSc, MRCP, Catherine Ogilvie, MD, Jennifer Travers, MD, Michelle Martin, Jonathan Allan, Pam McKay, MD, Mike Leach, MD

Blood (2019) 134 (Supplement_1): 5285.

https://doi.org/10.1182/blood-2019-126704

Published: 2019

Journal Articles

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Eldad J Dann, MD, Rebeca Lopez-Alonso, Shunan Qi, Tania Mashiach, Michal Weiler-Sagie, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 4051.

https://doi.org/10.1182/blood-2019-122824

Published: 2019

Journal Articles

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Nadav Ofshenko, Eyal Bercovich, Tania Mashiach, Michal Weiler-Sagie, Daniela Militianu, Eldad J Dann, MD

Blood (2019) 134 (Supplement_1): 4042.

https://doi.org/10.1182/blood-2019-122675

Published: 2019

Journal Articles

Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma

Sang Eun Yoon, Won Seog Kim, MD PhD, Seok Jin Kim, MD PhD, Young Hyeh Ko, MD, Kim Yeon Jeong, PhD, Park Donghyun, PhD

Blood (2019) 134 (Supplement_1): 1491.

https://doi.org/10.1182/blood-2019-130075

Published: 2019

Journal Articles

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Blood (2019) 134 (Supplement_1): 1564.

https://doi.org/10.1182/blood-2019-125256

Published: 2019

Journal Articles

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Patrizia Mondello, MD PhD MSc, Irene Dogliotti, MD, Jan-Paul Bohn, Federica Cavallo, Simone Ferrero, MD, Barbara Botto, Claudio Cerchione, MD PhD, Davide Nappi, Sonya De Lorenzo, Giovanni Martinelli, MD, Dominik Wolf, Univ. Prof. Dr., Giacomo Loseto, MD, Salvatore Cuzzocrea, MD PhD, Wolfgang Willenbacher, MD PhD, Michael Mian, MD

Blood (2019) 134 (Supplement_1): 1565.

https://doi.org/10.1182/blood-2019-128198

Published: 2019

Journal Articles

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Cassidy Brothers, MD MSC

Blood (2019) 134 (Supplement_1): 5631.

https://doi.org/10.1182/blood-2019-125378

Published: 2019

Journal Articles

Treatment Practices and Outcomes in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the Veterans Health Administration

Ahmad S Halwani, MD, Kelli M Rasmussen, MS, Vikas Patil, MS, Catherine Li, PhD, Christina Young, MA, Zachary Burningham, PhD, Mathias Schulz, MD MBA, Jia Li, PhD, Anthony Masaquel, PhD MPH, Mary Halloran, PharmD, Elisha Delong-Sieg, PharmD, Brian C Sauer, PhD

Blood (2018) 132 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2018-99-116695

Published: 2018

Journal Articles

Addition of Rituximab to High-Dose Methotrexate Regimens Improves Complete Response Rates and Median Overall Survival in Non-Germinal Center Primary CNS Lymphoma

Neelam Mistry, MD, Derek E Smith, MS, Manali Kamdar, MD, Bradley M. Haverkos, MD MPH, MS, Douglas Ney, MD

Blood (2018) 132 (Supplement 1): 4217.

https://doi.org/10.1182/blood-2018-99-112686

Published: 2018

Journal Articles

ST2 and ROR-γ-t Roles in Intestinal Regulatory T Cells

Jinfeng Yang, PhD, Abdulraouf Ramadan, PhD, Dawn Reichenbach, PhD, Michael Loschi, MD, Jilu Zhang, PhD, Brad Griesenauer, PhD, Hong Liu, MS, Keli Lee Hippen, PhD, Bruce R. Blazar, MD, Sophie Paczesny, MD PhD

Blood (2018) 132 (Supplement 1): 66.

https://doi.org/10.1182/blood-2018-99-113003

Published: 2018

Journal Articles

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Deborah M. Stephens, Hongli Li, MS, Heiko Schoder, MD, David J. Straus, MD, Craig H. Moskowitz, MD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Nancy L. Bartlett, MD, Andrew M. Evens, DO, MSc, Ann S. LaCasce, MD MSc, Paul Barr, MD, Michael V. Knopp, Eric D. Hsi, MD, John P. Leonard, MD, Brad S Kahl, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 929.

https://doi.org/10.1182/blood-2018-99-113034

Published: 2018

Journal Articles

Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Danielle Canioni, MD, Pauline Brice, MD, Serge Bologna, MD, Laurent Voillat, MD, Jean Gabarre, MD, Olivier Casasnovas, MD, Alain Devidas, MD, Bertrand Coiffier, MD PhD, Malek Aoudjhane, MD, Bruno Audhuy, MD, Marc Andre, MD, Catherine Fortpied, MD, Patrice Carde, MD PhD, Nicolas Mounier, MD, Josette Briere, MD

Blood (2018) 132 (Supplement 1): 4132.

https://doi.org/10.1182/blood-2018-99-118039

Published: 2018

Journal Articles

A Retrospective Study of 108 Cases of Relapsed or Refractory Classical Hodgkin Lymphoma: Second Line Therapies and Autologous Hematopoietic Stem Cell Transplantation

Mingzi Yang, MD, Meng Wu, MD, Reyizha Nuersulitan, MD, Yanfei Liu, MD, Liya A, MD, Lingyan Ping, MD PhD, Yuqin Song, MD PhD, Jun Zhu, MD PhD

Blood (2018) 132 (Supplement 1): 5361.

https://doi.org/10.1182/blood-2018-99-112385

Published: 2018

Journal Articles

Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

Abi Vijenthira, MD, Kelvin Chan, MD PhD, Matthew Cheung, MD MS, FRCP, Anca Prica, MD

Blood (2018) 132 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2018-99-113103

Published: 2018

Journal Articles

Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Karen E Effinger, MD MS, John Bergsagel, MD, Taylor Lawrence, Frank G Keller, MD, Rebecca Williamson Lewis, MPH, Lillian Meacham, MD, Ann Mertens, PhD, Sharon M. Castellino, MD MSc

Blood (2017) 130 (Supplement 1): 3466.

https://doi.org/10.1182/blood.V130.Suppl_1.3466.3466

Published: 2017

Journal Articles

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Eric D. Hsi, MD, Hongli Li, MS, Andrew B. Nixon, PhD, Andrew M Evens, DO,MSc, Heiko Schoder, MD, David J. Straus, MD, Nancy L. Bartlett, MD, John William Sweetenham, MDFRCP, Paul M. Barr, MD, Michelle A. Fanale, MD, James R. Cook, MD PhD, Brad S Kahl, MD, John P. Leonard, MD, Sonali M. Smith, MD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Jonathan W. Friedberg, MD, Oliver W. Press, MD PhD

Blood (2017) 130 (Supplement 1): 4033.

https://doi.org/10.1182/blood.V130.Suppl_1.4033.4033

Published: 2017

Journal Articles

The Cambridge University Hospitals and Anglia Regional Experience of Using PEP-C As Palliative Chemotherapy in Lymphoma

Simon J Bulley, Isabel C Lentell, Brendan O'Sullivan, Annabel M Follows, Shalal Sadullah, Mamatha Karanth, MD, Sandra Young Min, James Russell, MA,MBBChir,MRCP, Benjamin J Uttenthal, MD PhD, George A Follows, MD PhD

Blood (2017) 130 (Supplement 1): 4157.

https://doi.org/10.1182/blood.V130.Suppl_1.4157.4157

Published: 2017

Journal Articles

Patient and Physician Preferences for Front-Line Treatment of Advanced Stage Hodgkin Lymphoma in Germany, France and the United Kingdom

Paul Broeckelmann, Aspasia Stamatoullas, MD, Suzanne McMullen, Ben Wilson, MSc, Kerstin Mueller, MSc, MA, PhD, Sarah Goring, MSc, Erin Zagadailov, PharmD, MS, Ashish Gautam, PhD, Dirk Huebner, MD, Mehul Dalal, PhD, Tim M. Illidge, MDPhD

Blood (2017) 130 (Supplement 1): 4082.

https://doi.org/10.1182/blood.V130.Suppl_1.4082.4082

Published: 2017

Journal Articles

Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): Clinical Features, Treatment, and Outcome. a Single Institution Result of 145 Patients from the Middle East

Saad Akhtar, MD, Amani Al-Kofide, MD, Nasir Bakshi, MD, Mohammed Shamayel, MD, Yasser Khafaga, MD, Suleimman Al-Sweedan, MD, Tusneem Elhassan, MSc, M S Rauf, MD, Irfan Maghfoor, MD

Blood (2017) 130 (Supplement 1): 2794.

https://doi.org/10.1182/blood.V130.Suppl_1.2794.2794

Published: 2017

Journal Articles

Risk Adapted Treatment in Childhood Hodgkin's Lymphoma: Outcome and Changing Epidemiologic Features in 25 Years

Rejin Kebudi, MD Prof, Sema Bay Buyukkapu, MD, Omer Gorgun, MD, Fulya Yaman Agaoglu, MD, Bulent Zulfikar, MD, Inci Ayan, MD, Ayca Iribas, MD, Dizdar Yavuz, MD, Oner Dogan, MD, Emin Darendeliler, MD

Blood (2016) 128 (22): 4158.

https://doi.org/10.1182/blood.V128.22.4158.4158

Published: 2016

NARROW

ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Treatment Practices and Outcomes in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the Veterans Health Administration

Addition of Rituximab to High-Dose Methotrexate Regimens Improves Complete Response Rates and Median Overall Survival in Non-Germinal Center Primary CNS Lymphoma

ST2 and ROR-γ-t Roles in Intestinal Regulatory T Cells

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

A Retrospective Study of 108 Cases of Relapsed or Refractory Classical Hodgkin Lymphoma: Second Line Therapies and Autologous Hematopoietic Stem Cell Transplantation

Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

The Cambridge University Hospitals and Anglia Regional Experience of Using PEP-C As Palliative Chemotherapy in Lymphoma

Patient and Physician Preferences for Front-Line Treatment of Advanced Stage Hodgkin Lymphoma in Germany, France and the United Kingdom

Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): Clinical Features, Treatment, and Outcome. a Single Institution Result of 145 Patients from the Middle East

Risk Adapted Treatment in Childhood Hodgkin's Lymphoma: Outcome and Changing Epidemiologic Features in 25 Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only